World Vaccine Congress US 2015
Walter E. Washington Convention Center

Washington, USA
World Vaccine Congress US 2015 
Walter E. Washington Convention Center

Schedule of Presentations:

Tuesday, April 7, 2015
09:00:00 Chair’s opening remarks Greg Poland
09:10:00 Why scientists and physicians inhibit scientific advances: Historical examples and the role of cognitive biases and distortions in judgment and decision-making Greg Poland
09:40:00 New horizons for vaccine research and innovation: Aligning new technologies together for new possibilities Rino Rappuoli
10:10:00 The importance of developing vaccines for neglected infectious tropical diseases: Clinical advancement and partnerships Lance Gordon
11:40:00 Roundtable discussions on key vaccine topics
12:40:00 Networking lunch
14:10:00 Regulating vaccines at the FDA: The recent experience and moving forward Doran Fink
14:40:00 Ebola vaccine development: Controlling and containing outbreaks of Ebola Jerald C. Sadoff
15:45:00 bioCSL: Innovation past, present & future
16:10:00 Rapid response and control to influenza and MERS pandemics and outbreaks Gregory Glenn
16:35:00 What impact have recent changes in the vaccination ecosystem had on its future shape and sustainability Michael Watson
17:00:00 Gardasil 9: Building on the Success of Gardasil Paula Annunziato
17:25:00 Chair’s closing remarks and close of congress day one Greg Poland
Wednesday, April 8, 2015
09:00:00 Chair’s opening remarks
09:00:00 Chair’s opening remarks Klaus Stohr
09:00:00 Chair’s opening remarks Ronald Neeleman
09:00:00 Chair’s opening remarks Samir Khleif
09:00:00 Chair’s opening remarks George Siber
09:10:00 Technologies for the discovery and development of new vaccines Jeffrey Ulmer
09:10:00 Local disease prevention needs vs. global vaccine solutions Avner Finger
09:10:00 Anti-TGF-beta as a checkpoint inhibitor to promote tumor immunosurveillance and to enhance the efficacy of cancer vaccines
09:10:00 Novel immunological assays needed, future perspectives and requirements for regulatory agencies
09:10:00 Time for a big change – What needs to happen to launch a universal flu vaccine? Rick Bright
09:10:00 Does adjuvant particle size matter for immunogenicity and stability?
09:40:00 A cautionary tale for viral vaccine development: How changes in virus production process impact drug product stability characteristics
09:40:00 Low pathogenic avian influenza H9N2: A growing concern to poultry producers - How is the industry addressing this problem?
09:40:00 Advanced pre-clinical development of a novel recombinant lymphocytic choriomeningitis virus vector against cytomegalovirus
09:40:00 Engineering oncolytic Newcastle disease virus (NDV) for cancer therapy Hong Jin
09:40:00 Universal influenza vaccines: Protection against mismatch
09:40:00 Developing an Ebola vaccine using FastVax technology: Can we apply the power of computational vaccinology to the development of more effective vaccines? Anne S. De Groot
10:10:00 Exploring techniques and approaches for animal and human universal flu vaccines Chang-Won Lee
10:10:00 Photochemical internalization – an innovative technology giving strong enhancement of cytotoxic T-cell responses to peptide-and protein-based vaccines Anders Høgset
10:10:00 Fungal vaccines: Reporting progress of Phase I and II efficacy studies John Hennessey
10:10:00 The Promise of Prevention: Developing a universal novel vaccine virus, M2SR, based on deletion of a portion of the M2 gene Pamuk Bilsel
10:25:00 Successful use and clinical efficacy of live modified vector viruses in cancer immunotherapy vaccines
11:40:00 Amgen's viral cancer vaccine T-Vec tackles melanoma tumors in phase III Howard Kaufman
11:40:00 Clinical development of vaccines in Latin America
11:40:00 RSV Vaccines: Active and passive immunizations for the young and old Steve Projan
11:40:00 Ebola vaccine development: Utilizing the MVA-BN® platform to address national security and public health threats Lars Staal Wegner
11:40:00 How to build quality into the process during technology transfer GS Reddy
11:40:00 Utilization of next-generation sequencing (NGS) for selection of autogenous vaccine candidates
11:55:00 Strategies for Ebola vaccine production
12:10:00 Preventing the pandemic potential of MERS-CoV: Updates on research and clinical development Matthew Frieman
12:10:00 Global life-cycle management of vaccines: Solutions to root causes and issues Andrew Robertson
12:10:00 Development of a Middle East Respiratory Syndrome Coronavirus Vaccine Barney Graham
12:10:00 Immune education and immune modulation in cancer therapy
12:10:00 Positive top-line phase 1 results for a novel universal pneumococcus vaccine Chip Clark
12:40:00 Meeting analytical needs: Teal-time viral affinity quantification Ronald Neeleman
12:40:00 Early clinical development of a novel synthetic vaccine vector: Addressing effective antigen-cross presentation, immune modulation and overcoming immune suppression Frank Bedu Addo
12:40:00 Where are we in developing a vaccine against Staphylococcus aureus? Results from clinical phase II data Kathrin Jansen
12:40:00 Evaluating correlates of protection for influenza vaccines
12:40:00 Using computational techniques to develop an influenza vaccine Ted Ross
12:40:00 Controlling livestock diseases of economic importance – Who and what are Gates supporting and why? Samuel Thevasagayam
14:40:00 Phase II development of a prophylactic HIV vaccine Harriet L. Robinson
14:40:00 Novel delivery systems to facilitate or enhance the sub-optimal uptake of the cancer antigen and adjuvant by the antigen presenting cells Marc Mansour
14:40:00 Immunological assays for RSV vaccines: Evaluation and requirements for regulatory agencies Judy Beeler
14:40:00 Prophylactic vaccine against chikungunya
14:40:00 Novel self-amplifying mRNA vaccine platform without cell culture production
14:40:00 Control of food- and water-borne zoonotic diseases by vaccination of livestock Andrew Potter
15:10:00 Developing targeted immunotherapies and vaccines against cancer and difficult-to-treat infectious diseases: Utilizing a third generation adenovirus vector platform for immunization and “boost” Frank Jones
15:10:00 Panel: How much clinical efficacy is enough? Stephen L. Hoffman, John Hennessey
15:10:00 RSV vaccine: How to select reliable immunoassays and establishing correlates that can measure the efficacy
15:10:00 Developing vaccines against insect-borne viral diseases Malcolm Thomas
16:40:00 HyperAcute® Immunotherapy: A Whole-Cell Vaccine Approach to Cancer Treatment Eugene Kennedy
16:40:00 Panel: Addressing allergy and autoimmune disorders with similar approaches: How do clinical approaches differ to other disease areas and what can we learn from each other? Leslie J. Williams, Jerónimo Carnés
16:40:00 Advancing through phase II clinical trials in developing an RSV vaccine through recombinant technology Gregory Glenn
16:40:00 The race for a malaria vaccine: Prevention vs. Eradication Stephen L. Hoffman
16:40:00 Where are prophylactic vaccines heading? GS Reddy
16:40:00 Case study and Q&A: How to evaluate new technology and self-derived platforms that deviate from “classic” vaccine development Byron Rippke
16:55:00 Presenting effective immunotherapy against melanoma in an animal study
17:10:00 Strong T-cell immune response elicited by plant-made pandemic H5 influenza VLP vaccine
17:10:00 Active specific immunotherapy: Using tumour heterogeneity to successfully fight cancer Michael G. Hanna
17:10:00 Vaccines against Dengue: Challenges and opportunities Danilo Casimiro,
17:40:00 The future shape of Vaccine Biomanufacturing: Challenges ahead and potential solutions Matthew Sanders
17:40:00 Breakthrough technology platform: Advancing through development with VLP vaccines
17:40:00 Case study: The first USDA conditional licensure of a Porcine Epidemic Diarrhea Virus (PEDv) vaccine using RNA platform Hank Harris
17:55:00 New prophylactic solutions in animal health and opportunities in human vaccine arena Pascal Breton
18:05:00 Key factors for success in publishing vaccine clinical trials Anne Hepburn
18:10:00 High density display of antigens on the surface of bacterial OMVs elicits protective responses Joen Luirink
18:10:00 Manufacture and purification of a third generation VLP for Cytomegalovirus
18:10:00 The beginning of a long journey ahead: What is the future of current veterinary vaccine approaches in RNA vaccines?
18:20:00 Optimizing intradermal injection for high-value and emerging market vaccines Zach Marks
18:25:00 Gaps in knowledge of RSV epidemiology and pathogenesis – The importance for vaccine development Louis Bont
18:25:00 The shift towards cell-based vaccines: Production obstacles of non-traditional cell-based vaccines
18:40:00 Chair closing remarks
18:40:00 Chair's closing remarks Ronald Neeleman
18:40:00 Chair’s closing remarks George Siber
18:40:00 Chair’s closing remarks Klaus Stohr
18:40:00 Chair's closing remarks Samir Khleif
21:00:00 Chair’s opening remarks Samir Khleif
Thursday, April 9, 2015
06:00:00 New Presentation
09:00:00 Chair’s opening remarks Ronald Neeleman
09:00:00 Chair’s opening remarks Joseph Sullivan
09:00:00 Chair’s opening remarks
09:00:00 Chair’s opening remarks Lance Gordon
09:00:00 Chair’s opening remarks Klaus Stohr
09:10:00 Breakthrough therapy designation from FDA for innovative pancreatic cancer combination immunotherapy Dirk Brockstedt
09:10:00 How to translate bench research to clinical manufacturing Xun Liu
09:10:00 Translational discoveries that have led to improving manufacturing needs for new vaccine cell line substrates Ralph Tripp
09:10:00 Adjuvants and delivery systems as potential enabling technologies for emerging infectious diseases Sevda Senel
09:10:00 Launching discovery partnerships with industry and academia Rita Khanna
09:10:00 Intervention strategies to support the global control and eradication of foot-and-mouth disease virus
09:40:00 Panel: Collaborative partnerships with not-for-profit organizations and industry to allow research and manufacturing for global reach Andrew Robertson
09:40:00 How are veterinary vaccines changing in India? GS Reddy
09:40:00 RepliVax: A novel single-cycle vaccine approach to flavivirus and non-flavivirus targets Konstantin Pugachev
09:40:00 Translating the promise of DNA vaccines and immunotherapies into clinical efficacy: VGX-3100 Phase II clinical study for the treatment of cervical neoplasias
09:40:00 Getting prepared: Designing, testing and manufacturing effective vaccines for a pandemic
09:40:00 Continuous manufacturing: Industry efforts and lessons learned
10:10:00 The challenges in developing an effective leishmaniasis vaccine Steven Reed
10:10:00 Changing the conversation in malignant prostate cancer: Establishing the role of DNA vaccines
10:10:00 Human Viral Challenge Studies; accelerating drug development
10:10:00 Replication-deficient adenovirus as a delivery vector for animal health vaccines Scot Roberts
10:25:00 DCVax®: Novel Personalized Immune Therapies for Solid Tumors Linda Powers
11:30:00 Advances towards a prophylactic vaccine against Onchocerca volvulus Sara Lustigman
11:30:00 Updates on plant-produced Influenza and manufacturing Vidadi Yusibov
11:30:00 To what extent are disposable technologies the better choice for rapid and effective delivery of vaccines?
11:30:00 Transforming animal vaccines: Next generation technologies for better delivery
11:30:00 Sanofi Pasteur’s external collaborative research and partnering opportunities for vaccine development Roman Chicz
11:30:00 Realizing the promise of combination cancer immunotherapies Harlan Robins, Dirk Brockstedt
12:00:00 Vaccines for neglected infectious diseases: Schistosomiasis research and progress Afzal A Siddiqui
12:00:00 Solutions to funding difficulties for biopharmaceutical companies and start-ups Christopher Egerton-Warburton
12:00:00 How have veterinary vaccines been developed to help companion animals suffering from cancer? Michael Lawman
12:00:00 IRF-3 Agonists as Innate Immune Adjuvants: The potential to broaden vaccine activity and provide more effective protection Shawn Iadonato
12:00:00 Globalization of conjugate vaccines for unmet needs – Addressing specific product characteristics that can be implemented early in R&D and bioprocessing for worldwide suitability Manoj Kumar
12:15:00 Current successes and future trends in mammalian cell line-based influenza vaccine development
13:30:00 Chair opening remarks Joseph Sullivan, Greg Poland
13:40:00 Vaccine development for re-emerging outbreaks e.g. whooping cough Nathalie Mielcarek
13:40:00 Finding a partner to progress clinical development: Aligning R&D, technology and expertise with business development
14:10:00 Monitoring vaccine safety in a globalized health market Walter Strauss
14:10:00 NIAID Resources and opportunities for vaccine research Cristina Cassetti
14:40:00 A national strategy for adult vaccines and vaccinations Bruce Gellin
14:40:00 Vaccine Partnerships in Europe - Maintaining a healthy relationship: How to measure performance of the alliance Odile Leroy
15:10:00 Chair’s closing remarks Joseph Sullivan, Greg Poland
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.